Current treatment strategies for pancreatic cancer in the elderly

Drugs and Aging

Volumn 23, Issue 5, 2006, Pages 403-410

  Hanada, Keiji ^a   Hino, Fumiaki ^a   Amano, Hajime ^a   Fukuda, Toshikatsu ^a   Kuroda, Yoshinori ^a  

^a ONOMICHI GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; MARIMASTAT; OPIATE DERIVATIVE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SEMAXANIB;

ADVANCED CANCER; ANALGESIA; ASCITES; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; ENDOSCOPY; GENE INACTIVATION; GENE MUTATION; HEPATOBILIARY SYSTEM; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE JAUNDICE; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREAS SECRETION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STENT; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; AGING; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PAIN; PALLIATIVE CARE; PANCREATIC NEOPLASMS;

EID: 33745899640     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623050-00004     Document Type: Review

References (55)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37: 4-66
3. Cancer statistics in Japan 2001: Foundation for the Promotion of Cancer Research, 2001 [online]. Available from URL: http://www.ncc.go.jp [Accessed 2006 May 1]
4. SEER. SEER cancer statistics review, 1975-2003 [online]. Available from URL: http://seer.cancer.gov/csr/1975_2003 [Accessed 2006 May 17]
5. Albert BL, Patrick M. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004; 34: 238-44
6. Niederhuber JE, Brennan MF, Menck HR, et al. The national cancer database report on pancreatic cancer. Cancer 1995; 76: 1671-6
7. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7
8. Tanaka S, Kitamura T, Yamamoto K, et al. Evaluation of routine sonography for early detection of pancreatic cancer. Jpn J Clin Oncol 1996; 26: 422-7
9. Lynch HT, Brand RE, Lynch JF, et al. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 12-31
10. Ariyama J, Suyama M, Satoh K, et al. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 1998; 16: 396-401
11. Numata K, Yutaka O, Noritoshi K, et al. Contrast-enhanced sonography of pancreatic carcinoma: correlations with pathological findings. J Gastroenterol 2005; 40: 631-40
12. Sofuni A, Iijima H, Moriyasu F, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005; 40: 518-25
13. Yasuda K, Mukai H, Nakajima M, et al. Staging of pancreatic carcinoma by endoscopic ultrasonography. Endoscopy 1993; 25: 151-5
14. Gress GF, Hawes RH, Savides TJ, et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single center experience. Gastrointest Endosc 1999; 50: 786-91
15. Fujita N, Noda Y, Kobayashi G, et al. Endoscopic approach to early diagnosis of pancreatic cancer. Pancreas 2004; 28: 279-81
16. Ryozawa S, Kitoh H, Gondo T, et al. Usefulness of endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of pancreatic cancer. J Gastroenterol 2005; 40: 907-11
17. Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasm. Am J Surg 1994; 16: 104-11
18. Ly JN, Miller FH. MR imaging of the pancreas: a practical approach. Radiol Clin North Am 2002; 40: 1289-306
19. Saisho H, Yamaguchi T. Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 2004; 28: 273-8
20. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004; 11: 4-10
21. Ishimaru S, Itoh M, Hanada K, et al. Immunocytochemical detection of p53 protein from pancreatic duct brushing in patients with pancreatic carcinoma. Cancer 1996; 7: 2233-9
22. Sato Y, Nio Y, Song M, et al. p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997; 17: 2779-88
23. Jacobson SD, Alberts SR, O'Connell MJ, et al. Pancreatic cancer in the older patient. Oncology 2001; 15: 926-32
24. Gloor B, Ahmed Z, Uhl W, et al. Pancreatic disease in the elderly. Best Pract Res Clin Gastroenterol 2002; 16: 159-70
25. Hodul P, Tansey J, Golts E, et al. Age is not a contraindication to pancreaticoduodenectomy. Am Surg 2001; 136: 391-8
26. Sohn TA, Yeo CJ, Cameron JL, et al. Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg 1998; 2: 207-16
27. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-94
28. Bathe OF, Levi D, Caldera H, et al. Radical resection of periampullary tumors in the elderly: evaluation of long-term results. World J Surg 2000; 24: 353-8
29. Fong Y, Blumgart LH, Fortner JG, et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995; 222: 426-37
30. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903
31. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006-10
32. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-85
33. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
34. Neuhaus H, Oettle S, Post K, et al. A randomized, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2005; 24: 4013
35. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363: 1049-57
36. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high-dose (6000 rads) radiation alone, moderate-dose radiation (4000 rads + 5-fluorouracil), and high-dose radiation + 5-fluorouracil. Cancer 1981; 48: 1705-10
37. Magnino A, Gatti M, Massucco P, et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 2005; 68: 493-9
38. Morizane C, Okusaka T, Ito Y, et al. Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients. Oncology 2005; 68: 432-7
39. Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 1999; 9 Suppl. 1: 53-7
40. Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004; 136: 1003-11
41. Hanada K, Amano H, Hirano N, et al. The therapeutic strategy with special attention to quality of life in elderly patients with inoperable pancreatic carcinoma [in Japanese]. J Geriatric Gastroenterol 2005; 17: 33-7
42. Homma H, Doi R, Mezawa S, et al. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000; 89: 303-13
43. Shah JN, Muthusamy VR. Endoscopic palliation of pancreaticobiliary malignancies. Gastrointest Endosc Clin N Am 2005; 15: 513-31
44. Hanada K. Management for obstructive jaundice in the elders [in Japanese with English abstract]. J Jpn Conf Geriatric Gastroenterol 2001; 3: 86-91
45. Isayama H, Komatsu Y, Tsujino T, et al. Polyurethane-covered metal stent for management of distal malignant biliary obstruction. Gastrointest Endosc 2002; 55: 366-70
46. Isayama H, Komatsu Y, Tsujino T, et al. A prospective randomized study of 'covered' versus 'uncovered' diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53: 729-34
47. Yamazaki S, Kuramoto K, Itoh Y, et al. Clinical significance of portal venous metallic stent placement in recurrent periampullary cancers. Hepatogastroenterology 2005; 52: 191-3
48. Lilliemoe KD, Pitt HA. Palliation surgical and otherwise. Cancer 1996; 78: 605-14
49. Gunaratnam NT, Sarma AV, Norton ID, et al. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001; 54: 316-24
50. Levy MJ, Wiersema MJ. EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc 2003; 57: 923-30
51. Iwao T, Hanada K, Tsuchida A, et al. The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 1998; 82: 1487-94
52. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54
53. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine and radiation. Int J Radiat Oncol Biol Phys 2002; 54: 1180-93
54. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004; 22: 2610-6
55. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract]. Proc Am Soc Clin Oncol 2005; 24: 1